Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Clavis' Hellebø takes the helm at Sir Chris Evans-backed ReNeuron

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Calico's Levinson leaves Roche board to focus on AbbVie R&D deal

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Legendary Genentech CEO Levinson cuts last ties with Roche

Roche wanted to hang on to former Genentech CEO Art Levinson after buying out his company in 2009. But after a 5-year board stint, Levinson--now the chief exec at Google's Calico--is saying his goodbyes.

GSK investors call for chairman's head after sorry Q2, bribery probes

GlaxoSmithKline Chairman Christopher Gent says he'll step down at the end of 2015. But thanks to sweeping corruption allegations and a languishing stock price, shareholders want change at the top now, the Sunday Times reports.

Sanofi appoints Japan exec to lead U.S. pharma ops

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Sanofi brings Japan exec to U.S. to fill empty pharma chief's shoes

Sanofi has a new North American chief. The French drugmaker has slotted Jez Moulding into the slot Anne Whitaker suddenly vacated a few weeks ago. He'll head up the North American pharma business after serving as SVP of the company's Japan and Pacific operations.

Galena says goodbye to ex-CEO, no severance pay included

Galena Biopharma announced a new CEO last week. The outgoing chief, Mark Ahn, was said to be leaving to pursue "other long-held personal and professional goals." That's an obvious red flag: Ahn must have been not-so-gently reminded that he had other long-held goals.

Allergan CFO steps down amid buyout drama, but analysts aren't concerned

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Allergan CFO's departure may signal strength, not weakness

The sudden departure of a C-suite exec always raises eyebrows. When the company is a buyout target in the midst of a heated takeover battle, the questions really fly. But in the case of Allergan CFO Jeff Edwards, whose departure the company announced Monday, analysts say there's nothing to worry about.

Former Warner Chilcott CFO Paul Herendeen takes that spot at Zoetis

Paul Herendeen has been appointed as the new executive vice president and chief financial officer to Zoetis, the animal health industry leader. Reporting to CEO Juan Ramón Alaix, he will oversee the company's finance and IT segments.